Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to: navigation, search
m (Profile Development)
m
 
(42 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
 
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
'''Secretary''': Julie Lisiecki
+
 
 +
'''RSNA Staff Support''': Julie Lisiecki
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 +
  
 
==Meetings==
 
==Meetings==
Line 7: Line 9:
 
'''Recent Call Summaries:'''
 
'''Recent Call Summaries:'''
  
*[[Media: 2019 01 28 QIBA CT Angiography_FINAL.pdf | January 28, 2019]]
+
*[[Media: 2020 06 16 QIBA CT Angiography_FINAL.pdf | June 16, 2020]]
*[[Media: 2019 01 14 QIBA CT Angiography_FINAL.pdf | January 14, 2019]]
+
*[[Media: 2020 04 24 QIBA CT Angiography_FINAL.pdf | April 24, 2020]]
*[[Media: 2018 12 17 QIBA CT Angiography_FINAL.pdf | December 17, 2018]]
+
*[[Media: 2019 11 12 QIBA CT Angiography_SME_FINAL-2.pdf | November 12, 2019 (SME call)]]
*[[Media: 2018 11 19 QIBA CT Angiography_FINAL.pdf | November 19, 2018]]
+
*[[Media: 2018 11 05 QIBA CT Angiography_FINAL.pdf | November 5, 2018]]
+
*[[Media: 2018 10 22 QIBA CT Angiography_FINAL.pdf | October 22, 2018]]
+
*[[Media: 2018 10 08 QIBA CT Angiography_FINAL.pdf | October 8, 2018]]
+
*[[Media: 2018 09 24 QIBA CT Angiography_FINAL.pdf | September 24, 2018]]
+
*[[Media: 2018 08 27 QIBA CT Angiography_FINAL.pdf | August 27, 2018]]
+
*[[Media: 2018 08 13 QIBA CT Angiography_FINAL.pdf | August 13, 2018]]
+
*[[Media: 2018 07 30 QIBA CT Angiography_FINAL.pdf | July 30, 2018]]
+
  
 
'''''[[CT Angiography Call Summaries Archive]]'''''
 
'''''[[CT Angiography Call Summaries Archive]]'''''
Line 30: Line 24:
 
==Profile Development==
 
==Profile Development==
  
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-11-27-full.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | November 27, 2019]]
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-11-27.PDF | QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count) | November 27, 2019]]
 +
*[[Media:CTA Comments 2019-11-27.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | November 27, 2019]]
 +
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-10-30.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | October 30, 2019]]
 +
*[[Media:CTA Comments 2019-10-30.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | October 30, 2019]]
 +
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-09-09b.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | September 9, 2019]]
 +
*[[Media:CTA Comments 2019-09-09.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | September 9, 2019]]
 +
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-26.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 26, 2019]]
 +
*[[Media:CTA Comments 2019-08-26.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 26, 2019]]
 +
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-12.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 12, 2019]]
 +
*[[Media:CTA Comments 2019-08-12.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 12, 2019]]
 +
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-07-29.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | July 29, 2019]]
 +
*[[Media:CTA Comments 2019-07-29.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | July 29, 2019]]
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-26.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019]]
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-11.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019]]
 
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
 
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
 
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
 
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
 
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]
 
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]
*[[Media:2018_11-19_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | November 19, 2018]]
 
*[[Media:2018_11-05_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | November 5, 2018]]
 
*[[Media:2018_08-27_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | August 27, 2018]]
 
*[[Media:QIBA_Atherosclerosis Biomarkers Profile 2018-08-15.docx | QIBA Atherosclerosis Biomarkers Profile Draft | August 15, 2018]]
 
  
==Groundwork Projects==
+
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
  
 +
==Groundwork Projects==
  
 
==Reference Materials==
 
==Reference Materials==

Latest revision as of 18:01, 23 February 2021

Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT

RSNA Staff Support: Julie Lisiecki


Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials